Lyra Therapeutics (LYRA) Misses Q1 EPS by 1c

Lyra Therapeutics (NASDAQ: LYRA) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Truist Securities Downgrades Covista (CVSA) to Hold
• Phreesia Inc. (PHR) Misses Q2 EPS by 6c; Offers Guidance
• Bessent at Charlotte Private Luncheon warns China AI win would 'negate all else', targets 80% compute share by 2028